Median overall survival vs. control (13.7 vs 10.2 mo)
Ketogenic diet alongside chemo — well-tolerated, early signal
Randomized Phase 2 trial in metastatic pancreatic cancer. 94% of patients reached ketosis, no added toxicity, no decline in quality of life. Progression-free survival 8.5 vs 6.2 months. Larger trials needed.
Randomized Phase 2 trial — Cancer, 2025. PMID 41817106 →
